Clinical Trials Logo

Liver Diseases clinical trials

View clinical trials related to Liver Diseases.

Filter by:

NCT ID: NCT01390766 Completed - Liver Diseases Clinical Trials

Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)

Start date: August 2002
Phase: N/A
Study type: Observational

This post-marketing surveillance (PMS) study is designed to investigate the efficacy and safety of azathioprine tablets in Japanese subjects whom liver transplantation is performed.

NCT ID: NCT01381432 Completed - Liver Diseases Clinical Trials

Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)

Start date: December 2004
Phase: N/A
Study type: Observational

This post-marketing surveillance study is to investigate the efficacy and safety of azathioprine tablets in subjects whom lung transplantation is performed.

NCT ID: NCT01370148 Completed - Liver Disease Clinical Trials

A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

Start date: April 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmacokinetics and safety of a 48-hour continuous infusion of conivaptan in subjects with severe liver impairment compared to subjects with normal liver function.

NCT ID: NCT01331187 Completed - Dyspnea Clinical Trials

Influence of Routinely Adding Ultrasound Screening in Medical Department

Start date: April 1, 2011
Phase: N/A
Study type: Interventional

Ultrasound (US) is widely used as a diagnostic tool in a hospital setting. In a medical department, diagnosis like heart failure or most kinds of heart diseases, hypervolemia, hypovolemia, pleural effusion, pericardial effusion, ascites, diseases in the gall bladder/bile tract, urine tract and venous thrombosis are common. US is the key diagnostic tool in these diagnosis, and on early diagnosis is crucial with respect to the patients well-being and inpatients workflow. 1. The aim is to study the clinical use of pocket-size US as a screening diagnostic tool in an medical department with respect to inpatients workflow and diagnostics. Method: Patients admitted (in certain preset periods) to Department of medicine will be randomized to routinely adding an ultrasound examination with pocket-size device by residents on call. Time to definitive diagnosis, time to definitive treatment and time to discard will be recorded. US findings will be validated against standard echocardiography, or standard US/CT/MRI performed at the Radiological department.

NCT ID: NCT01324349 Completed - Liver Disease Clinical Trials

Comparison of the Hemostatic Patch to Fibrin Sealant (TachoSil®) in Subjects Undergoing Hepatic Surgery

Start date: February 2011
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of Covidien's Hemostatic Patch to control bleeding during hepatic surgery. The performance of the Hemostatic Patch will be compared to Control as an adjunct to conventional hemostatic techniques.

NCT ID: NCT01316679 Completed - Clinical trials for Hepatocellular Carcinoma

An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423

Start date: March 2011
Phase: N/A
Study type: Observational

Specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.

NCT ID: NCT01303549 Completed - Liver Disease Clinical Trials

Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

AVALTRA
Start date: November 2011
Phase: Phase 4
Study type: Interventional

The study is a randomized, open-label safety study comparing the use of anidulafungin (200 mg i.v. as initial dose and 100 mg/d i.v. in subsequent doses) vs liposomal amphotericin B (3 mg/kg/d i.v.) in hepatic transplant recipients who have high risk of fungal infection.

NCT ID: NCT01298063 Completed - Healthy Clinical Trials

Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib

Start date: February 2011
Phase: Phase 1
Study type: Interventional

Up to 38 subjects entered with the aim of entering 8 subjects with mild liver impairment (at highest dose of afatinib), 8 subjects with moderate liver impairment (at either highest dose or two lower doses) and 8 healthy matched controls to each of this two groups.

NCT ID: NCT01284049 Completed - Liver Diseases Clinical Trials

Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease

MEGANORM
Start date: November 2011
Phase: N/A
Study type: Interventional

The objective of the study is to show that substitution of the usual lipid emulsion (Intralipid 20%®) at a dose between 0.5 and 1.0 g/kg/infusion of parenteral nutrition (n-6:n-3 ratio = 7:1) by an equivalent dose of 0.5 to 1 g/kg/infusion of another lipid emulsion, OMEGAVEN 10%® very rich in omega-3 (n-3) (n-6:n-3 ratio = 1:7) induces regression of PNALD due to the anti-inflammatory and anti-fibrotic effects of n-3 EFA. Regression of liver disease will be defined by normalization of the five liver function tests (LFT): conjugated bilirubin, gamma GT, alkaline phosphatase, AST and ALT transaminases.

NCT ID: NCT01237574 Completed - Metabolic Diseases Clinical Trials

Multicentre Prospective Cohort Study of Patients With Chronic Alcoholic and/or Metabolic Liver Disease

CALMET
Start date: November 23, 2010
Phase:
Study type: Observational

Chronic alcoholic and metabolic liver diseases are the two main liver diseases in France. The long-term prognosis of these two diseases are not well known because main studies are retrospective and with only alcoholic patients. The knowledge of the natural history of these diseases should improve the management of patients with such diseases. The aim of this prospective cohort is to describe the natural history of patients with chronic liver disease due to alcohol or metabolic disease and to identify factors associated with complications of these liver diseases (cirrhosis, hepatocellular carcinoma, ascites. ..).